Access cutting-edge melanoma treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.
Access melanoma specialists in Kansas City at no cost
This study follows strict safety protocols and ethical guidelines
All study-related melanoma treatment provided free
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Sponsor: Erasca, Inc.
Check if you qualify for this melanoma clinical trial in Kansas City, KS
If you're searching for melanoma treatment options in Kansas City, KS, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.